Pfizer targets VEGF bispecific white space
The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
FDA red and green lights: April 2026
Full US approval of Gilead’s Tecartus was the only positive decision last month.
Pfizer bags a hormone-sensitive win
Talapro-3 could help move Talzenna into earlier prostate cancer.
Pfizer touts atirmociclib success
But this comes in second-line breast cancer, a use the group isn’t pursuing.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
